Warner Chilcott PLC (WCRX): Today's Featured Health Care Loser
Warner Chilcott (WCRX) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.3%. By the end of trading, Warner Chilcott fell 32 cents (-1.6%) to $20.12 on average volume. Throughout the day, 2.8 million shares of Warner Chilcott exchanged hands as compared to its average daily volume of 3.2 million shares. The stock ranged in price between $19.92-$20.51 after having opened the day at $20.44 as compared to the previous trading day's close of $20.44. Other company's within the Health Care sector that declined today were: MediciNova (MNOV), down 42.9%, Catalyst Pharmaceutical Partners (CPRX), down 34.5%, Urologix (ULGX), down 13.7%, and Senesco Technologies (SNT), down 9.3%. Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. Warner Chilcott has a market cap of $5.03 billion and is part of the drugs industry. The company has a P/E ratio of 13.3, below the average drugs industry P/E ratio of 16.6 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and four rate it a hold. TheStreet Ratings rates Warner Chilcott as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, compelling growth in net income, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated.
- You can view the full Warner Chilcott Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about WCRX
-
Quick Take: Fund Manager All-In On Actavis, Visa
01:52PM 06/18/13
-
Cramer's 'Mad Money' Recap: Don't Fear the Fed
08:37PM 06/17/13
-
The Deal: Actavis Extends Gains Following Warner Deal
03:31PM 05/21/13
-
Stocks Slip on Concerns Markets Overpriced
04:29PM 05/20/13
-
Ireland Welcomes Watson Pharmaceuticals, an American Success
02:27PM 05/20/13
-
The Deal: Actavis Plays Hunter in $8.5 Billion Deal for Ireland's Warner Chilcott
10:01AM 05/20/13
-
Futures Slip as Investors Seek Fed Clarity
09:13AM 05/20/13
Latest from TheStreet Wire
-
Abbott Laboratories (ABT): Today's Featured Health Services Laggard
05:22PM 06/19/13
-
Petroleo Brasileiro SA Petrobras (PBR): Today's Featured Basic Materials Laggard
05:01PM 06/19/13
-
Microsoft Corporation (MSFT): Today's Featured Computer Software & Services Laggard
05:01PM 06/19/13
-
Target Corp (TGT): Today's Featured Services Laggard
05:01PM 06/19/13
-
Teck Resources Ltd (TCK): Today's Featured Metals & Mining Laggard
05:01PM 06/19/13
-
United Technologies Corp (UTX): Today's Featured Industrial Laggard
05:01PM 06/19/13
-
Texas Instruments Inc. (TXN): Today's Featured Electronics Laggard
05:01PM 06/19/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
